by The Roskamp Institute | Mar 21, 2019 | News
Very unfortunately, today Biogen announced that it’s late-stage clinical trials for Alzheimer’s Disease using the drug Aducanumab have failed. Aducanumab was designed to target one of the main pathologies in Alzheimer’s Disease, namely, amyloid accumulation....
by The Roskamp Institute | Nov 19, 2018 | News
From the Executive Director, Dr. Michael Mullan: Alzheimer’s Update from the International Clinical Trials in Alzheimer’s Meeting (CTAD), Spain 2018. The annual meeting of the world’s leading Alzheimer’s Disease clinical trial experts from both academia and industry...
by The Roskamp Institute | Nov 12, 2018 | News
We’d like to say thank you to all the veterans and supporters that showed up for our open house this year. We were absolutely blown away by the number of people engaging with our scientists and learning about our research projects. We hope you enjoyed talks on...
by The Roskamp Institute | Oct 1, 2018 | News
From the Executive Director, Dr. Michael Mullan The next few years are going to be very critical in our understanding of Alzheimer’s Disease and consequently for our search for new treatments. Most importantly, studies currently underway around the world are directly...
by The Roskamp Institute | Jul 6, 2018 | News
The Roskamp Institute is pleased to announce that its second annual seminar, Grey Matters—A Symposium on Alzheimer’s Disease Research, is nearly sold out. “We are thrilled with the outpouring of support for our Grey Matters event. The level of interest speaks to the...
by The Roskamp Institute | Dec 21, 2017 | News
A research project at The Roskamp Institute has demonstrated for the first time that mild Traumatic Brain Injury (mTBI) or concussion can precipitate a lifelong degenerative process in the brain. The findings of this study, led by Dr. Fiona Crawford and conducted by...
